Ascendis Pharma A/S is a Denmarkâ€‘based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.

Employees

1,189

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/26/19	237.98 $	+0.14%	5,07,658
18/26/18	237.64 $	-1.19%	5,83,990
15/26/15	240.50 $	-2.03%	4,71,347
14/26/14	245.49 $	+0.78%	2,78,119
13/26/13	243.58 $	+2.50%	4,32,458

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

205.26EUR

Average target price

256.03EUR

Spread / Average Target

+24.73%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:01 20/05/2026 am IST			5-day change	1st Jan Change
237.98 ^USD	+0.14%		+0.14%	+11.44%

18/05	European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading	MT
13/05	European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	MT

Capitalization	1.27TCr 1.48TCr 1.17TCr 1.1TCr 2.03TCr 1,43100Cr 2.09TCr 14TCr 5.42TCr 67TCr 5.55TCr 5.43TCr 2,35200Cr	P/E ratio 2026 *	15x	P/E ratio 2027 *	22.1x
Enterprise value	1.19TCr 1.37TCr 1.09TCr 1.03TCr 1.89TCr 1,33000Cr 1.94TCr 13TCr 5.04TCr 63TCr 5.16TCr 5.05TCr 2,18700Cr	EV / Sales 2026 *	8.83x	EV / Sales 2027 *	5.78x
Free-Float	95.9%	Yield 2026 *	-	Yield 2027 *	-

18/05	European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading	MT
13/05	European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	MT
08/05	Ascendis Pharma A/S, Q1 2026 Earnings Call, May 07, 2026
07/05	Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading	MT
07/05	Earnings Flash (ASND) Ascendis Pharma Posts Q1 Non-IFRS EPS 0.27 Euro	MT
07/05	Ascendis Pharma Swings to Q1 Earnings, Revenue Rises	MT
07/05	The Rally Spreads
07/05	Ascendis Pharma A/S Announces New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years	CI
04/05	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight
04/05	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight
22/04	European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading	MT
22/04	Ascendis Pharma to Redeem Senior Notes due 2028	MT

03/03	RBC Lifts Price Target on Ascendis Pharma to $275 From $250, Keeps Outperform, Speculative Risk	MT
12/02	Ascendis Pharma Shows Steady Progress Toward Long-Term Growth, Wedbush Says	MT
12/02	Oppenheimer Adjusts Ascendis Pharma Price Target to $262 From $246, Maintains Outperform Rating	MT
12/02	Wedbush Raises Price Target on Ascendis Pharma to $273 From $240, Keeps Outperform Rating	MT
28/01	Barclays Initiates Coverage on Ascendis Pharma With Overweight Rating, $342 Price Target	MT

Ascendis Pharma A/S Share Price

Equities

ASND

DK0060615755

Biotechnology & Medical Research

Valuation: Ascendis Pharma A/S

Chart: Ascendis Pharma A/S

Latest news : Ascendis Pharma A/S

Last Transcript: Ascendis Pharma A/S

Analysts' recommendations: Ascendis Pharma A/S

Press Releases: Ascendis Pharma A/S

News in other languages: Ascendis Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Ascendis Pharma A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07/05	Ascendis Pharma Reports First Quarter 2026 Financial Results	AQ
07/05	Ascendis Pharma A/S : PES 2026 ApproaCH 2-Year Subgroup Data	PU
07/05	New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years	AQ
01/05	Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026	AQ
22/04	Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028	AQ

07/05	Bourse : Engie, Bouygues et Legrand au révélateur, pluie de résultats en Europe
07/05	Le rebond se propage
11/11	Agenda van bedrijfsresultaten voor de week van 10 tot 14 november 2025: Chinese technologie, CoreWeave, Alstom en Vallourec in aantocht
13/25/13	En direct des marchés : EssilorLuxottica brille encore, Alibaba flambe, Chevron taille dans ses effectifs
13/25/13	Insubmersibles

1 week	234.08	248
1 month	216.22	250.27
Current year	216.22	250.27
1 year	216.22	250.27
3 years	216.22	250.27
5 years	216.22	250.27
10 years	216.22	250.27

Manager	Title	Age	Since
Jan Mikkelsen CEO	Chief Executive Officer	67	01/12/2007
Scott Smith DFI	Director of Finance/CFO	53	08/08/2016
Aimee Shu CTO	Chief Tech/Sci/R&D Officer	50	01/07/2017

Director	Title	Age	Since
Jan Mikkelsen BRD	Director/Board Member	67	01/12/2007
Albert Cha CHM	Chairman	54	28/05/2021
Lisa Bright BRD	Director/Board Member	59	01/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ASCENDIS PHARMA A/S	+0.14%	+0.14%	-	-	1.48TCr
LONZA GROUP AG	+4.21%	+2.07%	-15.01%	-15.57%	4.16TCr
BEONE MEDICINES AG	+1.34%	-5.73%	+27.27%	+27.69%	3.26TCr
REVOLUTION MEDICINES, INC.	+2.03%	+1.08%	+268.90%	+469.83%	3.07TCr
IQVIA HOLDINGS INC.	+0.21%	-1.07%	+20.65%	-13.17%	2.88TCr
CELLTRION, INC.	-0.38%	-5.59%	+23.25%	+14.60%	2.57TCr
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-2.84%	+2.47%	+191.46%	+4,084.10%	1.37TCr
IONIS PHARMACEUTICALS, INC.	+1.82%	-2.62%	+116.99%	+88.42%	1.2TCr
EUROFINS SCIENTIFIC SE	+2.03%	+3.55%	+9.70%	+1.36%	1.23TCr
MEDPACE HOLDINGS, INC.	-0.18%	+0.04%	+37.23%	+99.12%	1.2TCr
Average	+0.84%	-0.99%	+75.60%	+528.49%	2.24TCr
Weighted average by Cap.	+1.27%	-1.73%	+68.32%	+348.86%

	2026 *	2027 *
Net sales	134.26Cr 155.67Cr 122.99Cr 116.22Cr 214.25Cr 15TCr 219.65Cr 1.47TCr 570.78Cr 7.09TCr 584.16Cr 571.7Cr 25TCr	194.5Cr 225.51Cr 178.17Cr 168.36Cr 310.38Cr 22TCr 318.19Cr 2.12TCr 826.87Cr 10TCr 846.25Cr 828.2Cr 36TCr
Net income	89Cr 103.71Cr 82Cr 77Cr 142.75Cr 10TCr 146.34Cr 976.52Cr 380.28Cr 4.73TCr 389.19Cr 380.9Cr 17TCr	63Cr 73Cr 57Cr 54Cr 100Cr 7.03TCr 102.45Cr 683.65Cr 266.23Cr 3.31TCr 272.47Cr 266.66Cr 12TCr
Net Debt	-90Cr -103.92Cr -82Cr -78Cr -143.03Cr -10TCr -146.62Cr -978.42Cr -381.03Cr -4.74TCr -389.95Cr -381.64Cr -17TCr	-151.29Cr -175.4Cr -138.59Cr -130.95Cr -241.42Cr -17TCr -247.5Cr -1.65TCr -643.16Cr -7.99TCr -658.22Cr -644.19Cr -28TCr